Evidence map›Paper›PMID 36685528›Full record

ReviewFrontiers in immunology2022

Current knowledge of targeted-release budesonide in immunoglobulin A nephropathy: A comprehensive review.

Jian Liao, Yijing Zhou, Xiuqin Xu, Ke Huang, Pengtao Chen, Yuhao Wu, Biao Jin, Qianlong Hu, Guanlin Chen, Shankun Zhao

Registry-linked trialOpen access · goldAbstract readCase ReportsReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03643965 (A Randomized, Double-blind, Placebo Controlled Study to Evaluate Efficacy and Safety of Nefecon in Patients With Primary IgA), which is not on this map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03643965 phase3completednot on this map

A Randomized, Double-blind, Placebo Controlled Study to Evaluate Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy at Risk of Progressing to End-stage Renal Disease (NefIgArd)

TypeinterventionalSponsorCalliditas Therapeutics ABRan2018 to 2023Enrolled365ConditionsPrimary IgA NephropathyArmsNefecon, Placebo oral capsule
3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Observational
  3. Article
  4. Enteric Budesonide Treatment in IgA Nephropathy.Kidney international reports · 2026
    Article
  5. Review
  6. Article
  7. Review
  8. Observational
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Jian LiaoDepartment of Nephrology, Jiaxing Hospital of Traditional Chinese Medicine, Jiaxing, Zhejiang,  China.
Yijing ZhouDepartment of Nephrology, Jiaxing Hospital of Traditional Chinese Medicine, Jiaxing, Zhejiang,  China.
Xiuqin XuDepartment of Nephrology, Jiaxing Hospital of Traditional Chinese Medicine, Jiaxing, Zhejiang,  China.
Ke HuangDepartment of Nephrology, Jiaxing Hospital of Traditional Chinese Medicine, Jiaxing, Zhejiang,  China.
Pengtao ChenDepartment of Clinical Medical School, Taizhou University, Taizhou, Zhejiang,  China.
Yuhao WuDepartment of Clinical Medical School, Taizhou University, Taizhou, Zhejiang,  China.
Biao JinDepartment of Clinical Medical School, Taizhou University, Taizhou, Zhejiang,  China.
Qianlong HuDepartment of Clinical Medical School, Taizhou University, Taizhou, Zhejiang,  China.
Guanlin ChenDepartment of Clinical Medical School, Taizhou University, Taizhou, Zhejiang,  China.
Shankun ZhaoDepartment of Urology, Taizhou Central Hospital (Taizhou University Hospital), Taizhou, Zhejiang,  China.
Taizhou University · CNFirst Hospital of Jiaxing · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunoglobulin A (IgA) nephropathy is a common autoimmune kidney disease. Accumulating studies showed that IgA nephropathy may be partially correlated with mucosal immune system dysfunction. Systemic corticosteroid treatment exerts an essential protective effect against renal deterioration in IgA nephropathy. However, long-term use of corticosteroids may cause systemic side effects. The novel targeted-release formulation (TRF) of budesonide has been shown to deliver the drug to the distal ileum with the aim of minimizing adverse events for patients with IgA nephropathy. In this review, we have summarized all the current evidence of the effects of TRF-budesonide protecting against IgA nephropathy. Three randomized controlled trials (RCTs), one cohort, two case reports, and an ongoing Phase 3 trial (Part B, NCT03643965), were under comprehensive review. These included studies demonstrated that TRF-budesonide could remarkably reduce proteinuria, hematuria, and creatinine, as well as preserve renal function. The local immunosuppressive effects exhibited by TRF-budesonide may represent a novel and promising approach to treating IgA nephropathy. However, the current evidence was only derived from limited trials. Therefore, more well-designed RCTs are still warranted to validate the curable profile of TRF-budesonide in treating IgA nephropathy.

Indexed as

BudesonideGlomerulonephritis, IGAAdrenal Cortex HormonesGlucocorticoidsHumansKidneyAdrenal Cortex HormonesBudesonideGlucocorticoidsbudesonideIgA nephropathyproteinuriarenal functiontargeted-release formulation

Identifiers

PMID36685528
PMCPMC9846030
OpenAlexW4313588619

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.